Influence of Fluorescent Probe Size and Cytochrome b5 on Drug-Drug Interactions in CYP2C9

Abstract

7-Methoxy-4-trifluoromethylcoumarin (MFC) has been used extensively in high-throughput screens for the identification of potential CYP2C9 interactions. More recently, additional probes from Invitrogen have been used. Vivid 2C9Green is the largest of the probes and has had limited prior characterization. The newseries of probes differ significantly from MFC andwere examined for their ability to identify interactions with 19 CYP2C9 substrates/inhibitors. The inhibition profiles depend largely on the physical differences between the fluorescent probe substrates. Cytochrome b5 (cyt b5) was also investigated for the ability to alter the inhibition profile of a given compound. The stoichiometric addition of cyt b5 caused an increase in Vmaxof MFC and Vivid 2C9 Green 4.4 and 1.7 times, respectively. Furthermore, cyt b5 imposes a steric component to the active site as the inhibition profiles were significantly affected in incubations with MFC. The addition of cyt b5 had limited impact on the inhibition profiles generated with Vivid 2C9Green. The K_m of Vivid 2C9 Green increased from 1.2 ± 0.2 µ Mto4.8 ± 0.3 µ Mas a result of cyt b5 addition. These results illustrate that multiple substrate probes may be necessary for screening drug-drug interaction in CYP2C9 and that cyt b5 effects can impart steric restraints on the CYP2C9 active site.

Keywords

CYP2C9 drug interactions fluorescent inhibition cytochrome b5

References

Guengerich FP : Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997;43:7-35.

Crespi CL and Stresser DM : Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 2000;44:325-331.

Tracy TS : Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 2003;4:341-346.

Miller VP , Stresser DM , Blanchard AP , Turner S , Crespi CL : Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci 2000;919:26-32.

Cohen LH , Remley MJ , Raunig D , Vaz AD : In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.

Egnell AC , Eriksson C , Albertson N , Houston B , Boyer S : Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 2003;307:878-887.

Hutzler JM , Wienkers LC , Wahlstrom JL , Carlson TJ , Tracy TS : Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 2003;410:16-24.

Wester MR , Yano JK , Schoch GA , Yang C , Griffin KJ , Stout CD , et al: The structure of human microsomal cytochrome P450 2C9 complexed with flurbiprofen at 2.0 A resolution. J Biol Chem 2004;279:35630-35637.

Yamaguchi Y , Khan KK , He YA , He YQ , Halpert JR : Topological changes in the CYP3A4 active site probedwith phenyldiazene: effect of interactionwith NADPH-cytochrome P450 reductase and cytochrome b5 and of site-directed mutagenesis. Drug Metab Dispos 2004;32:155-161.

10.

Schenkman JB , Jansson I : Themany roles of cytochrome b5. Pharmacol Ther 2003;97:139-152.

11.

Yamazaki H , Nakamura M , Komatsu T , Ohyama K , Hatanaka N , Asahi S , et al: Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 2002;24:329-337.

12.

Locuson CWII , Wahlstrom JL , Rock DA , Jones JP : A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 2003;31:967-971.

13.

Leemann T , Transon C , Dayer P : Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4•-hydroxylation in human liver. Life Sci 1993;52:29-34.

14.

Miners JO , Coulter S , Tukey RH , Veronese ME , Birkett DJ : Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996;51:1003-1008.

15.

Hamman MA , Thompson GA , Hall SD : Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997;54:33-41.

16.

Jones JP , He M , Trager WF , Rettie AE : Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 1996;24:1-6.

17.

Yamazaki H , Shimada T , Martin MV , Guengerich FP : Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. J Biol Chem 2001;276:30885-30891.

18.

Yamazaki H , Johnson WW , Ueng YF , Shimada T , Guengerich FP : Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4: characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apocytochrome b5. J Biol Chem 1996;271:27438-27444.

19.

Hutzler JM , Kolwankar D , Hummel MA , Tracy TS : Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 2002;30:1194-1200.